These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 32556602)

  • 1. Effect of food on the pharmacokinetics of the WEE1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors.
    Någård M; Ah-See ML; So K; Vermunt M; Thistlethwaite F; Labots M; Roxburgh P; Ravaud A; Campone M; Valkenburg-van Iersel L; Ottesen L; Li Y; Mugundu G
    Cancer Chemother Pharmacol; 2020 Jul; 86(1):97-108. PubMed ID: 32556602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors.
    Do K; Wilsker D; Ji J; Zlott J; Freshwater T; Kinders RJ; Collins J; Chen AP; Doroshow JH; Kummar S
    J Clin Oncol; 2015 Oct; 33(30):3409-15. PubMed ID: 25964244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors.
    Takebe N; Naqash AR; O'Sullivan Coyne G; Kummar S; Do K; Bruns A; Juwara L; Zlott J; Rubinstein L; Piekarz R; Sharon E; Streicher H; Mittra A; Miller SB; Ji J; Wilsker D; Kinders RJ; Parchment RE; Chen L; Chang TC; Das B; Mugundu G; Doroshow JH; Chen AP
    Clin Cancer Res; 2021 Jul; 27(14):3834-3844. PubMed ID: 33863809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adavosertib (AZD1775) does not prolong the QTc interval in patients with advanced solid tumors: a phase I open-label study.
    Någård M; Ah-See ML; Strauss J; Wise-Draper T; Safran HP; Nadeau L; Edenfield WJ; Lewis LD; Rekić D; Dota C; Ottesen LH; Li Y; Mugundu GM
    Cancer Chemother Pharmacol; 2023 Aug; 92(2):141-150. PubMed ID: 37368100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312).
    Cole KA; Pal S; Kudgus RA; Ijaz H; Liu X; Minard CG; Pawel BR; Maris JM; Haas-Kogan DA; Voss SD; Berg SL; Reid JM; Fox E; Weigel BJ
    Clin Cancer Res; 2020 Mar; 26(6):1213-1219. PubMed ID: 31857431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the effects of food on the single-dose pharmacokinetics of trametinib, a first-in-class MEK inhibitor, in patients with cancer.
    Cox DS; Papadopoulos K; Fang L; Bauman J; LoRusso P; Tolcher A; Patnaik A; Pendry C; Orford K; Ouellet D
    J Clin Pharmacol; 2013 Sep; 53(9):946-54. PubMed ID: 23893461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relative bioavailability of pediatric oral solution and tablet formulations of trametinib in adult patients with solid tumors.
    Cox DS; Allred A; Zhou Y; Infante JR; Gordon MS; Bendell J; Jones S; Burris H; Orford K
    Clin Pharmacol Drug Dev; 2015 Jul; 4(4):287-94. PubMed ID: 27136909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Food on the Pharmacokinetics of the Oral Docetaxel Tablet Formulation ModraDoc006 Combined with Ritonavir (ModraDoc006/r) in Patients with Advanced Solid Tumours.
    Vermunt MAC; de Weger VA; Janssen JM; Lopez-Yurda MI; Keessen M; Thijssen B; Rosing H; Huitema ADR; Beijnen JH; Marchetti S
    Drugs R D; 2021 Mar; 21(1):103-111. PubMed ID: 33464545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies.
    Williams DD; Peng B; Bailey CK; Wire MB; Deng Y; Park JW; Collins DA; Kapsi SG; Jenkins JM
    Clin Ther; 2009 Apr; 31(4):764-76. PubMed ID: 19446149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, Pharmacokinetics, and Clinical Activity of Adavosertib in Combination with Chemotherapy in Asian Patients with Advanced Solid Tumors: Phase Ib Study.
    Kato H; de Souza P; Kim SW; Lickliter JD; Naito Y; Park K; Kumar S; Mugundu GM; Bang YJ
    Target Oncol; 2020 Feb; 15(1):75-84. PubMed ID: 32034630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer.
    Cuneo KC; Morgan MA; Sahai V; Schipper MJ; Parsels LA; Parsels JD; Devasia T; Al-Hawaray M; Cho CS; Nathan H; Maybaum J; Zalupski MM; Lawrence TS
    J Clin Oncol; 2019 Oct; 37(29):2643-2650. PubMed ID: 31398082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Food (Low and High Fat) on Pharmacokinetics of FCN-159, a Selective MEK Inhibitor, in Healthy Chinese Males.
    Li J; Tan Y; Li K; Hui AM; Wu Z; Han P; Wei Z; Qiu J; Diao L; Wang X
    Adv Ther; 2023 Mar; 40(3):1074-1086. PubMed ID: 36627544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of a phase 1, randomized study evaluating the effects of food and diurnal variation on the pharmacokinetics of linifanib.
    Xiong H; Chiu YL; Ricker JL; LoRusso P
    Cancer Chemother Pharmacol; 2014 Jul; 74(1):55-61. PubMed ID: 24810181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma.
    Liu JF; Xiong N; Campos SM; Wright AA; Krasner C; Schumer S; Horowitz N; Veneris J; Tayob N; Morrissey S; West G; Quinn R; Matulonis UA; Konstantinopoulos PA
    J Clin Oncol; 2021 May; 39(14):1531-1539. PubMed ID: 33705205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of WEE1 Is Effective in
    Seligmann JF; Fisher DJ; Brown LC; Adams RA; Graham J; Quirke P; Richman SD; Butler R; Domingo E; Blake A; Yates E; Braun M; Collinson F; Jones R; Brown E; de Winton E; Humphrey TC; Parmar M; Kaplan R; Wilson RH; Seymour M; Maughan TS;
    J Clin Oncol; 2021 Nov; 39(33):3705-3715. PubMed ID: 34538072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI 853520.
    Verheijen RB; van der Biessen DAJ; Hotte SJ; Siu LL; Spreafico A; de Jonge MJA; Pronk LC; De Vos FYFL; Schnell D; Hirte HW; Steeghs N; Lolkema MP
    Target Oncol; 2019 Feb; 14(1):67-74. PubMed ID: 30742245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours.
    Devriese LA; Koch KM; Mergui-Roelvink M; Matthys GM; Ma WW; Robidoux A; Stephenson JJ; Chu QS; Orford KW; Cartee L; Botbyl J; Arya N; Schellens JH
    Invest New Drugs; 2014 Jun; 32(3):481-8. PubMed ID: 24346280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, open-label, 5-period, balanced crossover study to evaluate the relative bioavailability of eltrombopag powder for oral suspension (PfOS) and tablet formulations and the effect of a high-calcium meal on eltrombopag pharmacokinetics when administered with or 2 hours before or after PfOS.
    Wire MB; Bruce J; Gauvin J; Pendry CJ; McGuire S; Qian Y; Brainsky A
    Clin Ther; 2012 Mar; 34(3):699-709. PubMed ID: 22336488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of High-Fat Food on the Pharmacokinetic Profile and Safety of SAF-189s, an ALK/ROS1 Inhibitor, in Healthy Chinese Adults.
    Qin H; Tan Y; Diao L; Hui AM; Wu Z; Zhou Y; Sun J; Xiang X; Qiu J; Hu W
    Drugs R D; 2023 Dec; 23(4):465-473. PubMed ID: 37934354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer.
    Keenan TE; Li T; Vallius T; Guerriero JL; Tayob N; Kochupurakkal B; Davis J; Pastorello R; Tahara RK; Anderson L; Conway J; He MX; Shannon E; Godin RE; Sorger PK; D'Andrea A; Overmoyer B; Winer EP; Mittendorf EA; Van Allen EM; Shapiro GI; Tolaney SM
    Clin Cancer Res; 2021 Feb; 27(4):983-991. PubMed ID: 33257427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.